Wednesday, September 30, 2015

EyewireTV — Raindrop Near Vision Inlay PMA; MillennialEYE Live

In this week's EyewireTV, ReVision Optics submits to the FDA the fourth and final module of the company’s premarket approval application for the Raindrop near vision inlay; and Ocular Therapeutix submits a new drug application to the FDA for Dextenza (dexamethasone 0.4 mg) for the treatment of ocular pain following ophthalmic surgery. Also, future and current leaders in ophthalmology discuss the hottest topics from annual MillennialEYE Live meeting in Hollywood. (2137 Views)

Watch Video

Wednesday, September 23, 2015

EyewireTV — Rhopressa Back on Track; Sun Pharma Buys InSite

In this week's EyewireTV, glaucoma drug candidate Rhopressa achieves its primary efficacy endpoint in its second phase 3 trial, Rocket 2, and a subsidiary of Sun Pharmaceutical Industries, India’s largest pharmaceutical company, enters into an agreement to acquire InSite Vision for about $48 million. Also, the FDA accepts for review Bausch + Lomb’s new drug application for glaucoma drug candidate Vesneo (latanoprostene bunod 0.024%). (1826 Views)

Watch Video

Wednesday, September 16, 2015

EyewireTV — Coveted Product Approvals from Abroad

In this week’s EyewireTV, leading ophthalmologists from the United States and Europe discuss technologies and procedures currently available in Europe that they would like to see approved in the United States. (2254 Views)

Watch Video

Tuesday, September 08, 2015

EyewireTV — Breaking Industry News from the ESCRS Meeting in Barcelona

In this week's EyewireTV, Allergan President and CEO Brent Saunders talks about Allergan’s acquisition of AqueSys; and Heidelberg Engineering unveils a new cataract and refractive imaging platform. Also, Carl Zeiss Meditec receives FDA 510(k) clearance for its AngioPlex OCT Angiography, the first such technology to receive clearance in the United States. (4506 Views)

Watch Video

Wednesday, August 26, 2015

EyewireTV — Diagnosing MGD and DED; Contact Lens Survey

In this week’s EyewireTV, a large, government-sponsored survey shows that most adult contact lens wearers report behaviors that put them at risk for an eye infection; and Abbott Medical Optics announces the FDA approval and launch of three new cylinder powers for its Tecnis Toric IOL. In the weekly feature, three leading dry eye specialists discuss what cataract surgeons should do to make sure meibomian gland dysfunction and dry eye disease are addressed preoperatively. (2734 Views)

Watch Video

Wednesday, August 19, 2015

EyewireTV — Avastin vs Lucentis Safety Study; FDA Guidance on Ophthalmic Devices

In this week's EyewireTV, a government-sponsored study shows that injections of Avastin (bevacizumab, Genentech) to treat retina diseases pose no greater risk of endophthalmitis than injections with the more costly Lucentis (ranibizumab, Genentech); and in final guidance, the FDA said that international standards were insufficient to ensure IOL and other intraocular ophthalmic devices are free of bacteria upon manufacturing. Also, the FDA accepts for review InSite Vision’s new drug application for BromSite for the treatment of inflammation and prevention of postoperative pain. (3138 Views)

Watch Video

Wednesday, August 12, 2015

EyewireTV — iStent inject Clinical Trial; CXL in US Discussed

In this week's EyewireTV, Glaukos announces the completion of patient enrollment in its FDA trial for the iStent inject Trabecular Micro-Bypass Stent; and a government-sponsored study reveals that the number of people with diabetes who have had their eyes checked within the last year increases with age, but is still not optimal. In the feature, three leading ophthalmologists with experience performing corneal collagen cross-linking discuss the importance of having the procedure available in the United States. (2619 Views)

Watch Video

Wednesday, August 05, 2015

EyewireTV — Acquisition Expands Shire’s Pipeline; Victus Upgrade

In this week’s EyewireTV, Shire acquires Foresight Biotherapeutics, the maker of a conjunctivitis drug candidate, for $300 million, and makes an unsolicited offer to buy Baxalta, which sells treatments for rare bleeding disorders and immune deficiencies, for about $30 billion in stock; and Bausch + Lomb receives 510(k) clearance from the FDA for an enhanced patient interface kit for its Victus Femtosecond Laser Platform. In the feature, three femtosecond laser users discuss what they have learned while integrating the technology into their operating rooms. (2112 Views)

Watch Video

Wednesday, July 29, 2015

EyewireTV - Allergan Sells Generics Unit; Argus II for Dry AMD

In this week's EyewireTV, Teva, the world's largest generic drug company, agrees to acquire Allergan's generics unit for $40.5 billion in cash and stock; and Second Sight Medical Products announces the first implant and activation of the Argus II Retinal Prosthesis System in a dry AMD patient. Also, Opternative, a venture-backed startup, launches an online eye exam service that can provide a physician-issued prescription for glasses or contacts (2282 Views)

Watch Video

Wednesday, July 22, 2015

EyewireTV — LASIK System Launched in US; Best Ophthalmology Hospitals

In this week's EyewireTV, Abbott announces the FDA approval and launch of the iDesign Advanced WaveScan Studio System for personalized LASIK treatment; and Oertli obtains CE mark for its OS4 surgical platform for vitreoretinal, cataract, and glaucoma surgery. Also, US News & World Report releases its annual "Best Hospitals" list and for the 12th consecutive year, Bascom Palmer Eye Institute was ranked the top hospital in ophthalmology. (2127 Views)

Watch Video

Monday, July 13, 2015

EyewireTV — Will MIGS Transform Glaucoma?

In this week's special edition of EyewireTV, early adopters of microinvasive glaucoma surgery discuss how MIGS may transform the future of glaucoma treatment and management. (3144 Views)

Watch Video

Wednesday, July 08, 2015

EyewireTV — Allergan Acquires Dry Eye Candidate, Smart Watch App for Visually Impaired

In this week’s EyewireTV, Allergan agrees to acquire medical device maker Oculeve, developer of a non-invasive nasal neurostimulation device that increases tear production in dry eye patients; and Biogen enters into a major collaboration and licensing agreement with Applied Genetic Technologies Corporation (AGTC) to develop gene-based therapies for multiple ophthalmic diseases. Also, Novartis launches the first app for visually impaired people for use with smart watches. (2394 Views)

Watch Video
Load More